Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer.
Barrett AM, Britton ZT, Carrasco RA, Breen S, Broggi MAS, Hatke A, Clark B, Yang C, Phipps S, Ortiz L, Janocha B, Zanvit P, Giraldo NA, Martin PL, Lapointe JM, Harder N, Cornish GH, Attili BNNR, Mazor Y, Damschroder M, Cobbold M, Moody G, Bosco EE.
Barrett AM, et al. Among authors: britton zt.
Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-24-1853. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39321207